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A Community Hospital Antimicrobial 
Stewardship Program’s Assessment of
Prolonged Infusion 
Piperacillin-tazobactam for 
Pseudomonas Aeruginosa 
Pneumonia
By Lee Nguyen, PharmD, BCPS-AQ ID; Paul Gavaza, PhD; Amy Kang, PharmD;
An Nguyen, Liem Hoang, Nguyen Ta
Abstract
Background: The study aim was to determine and compare the length of hospitalization, mortality, clinical stability, and 
time to clinical stability of a standard infusion (SI) and prolonged infusion (PI) piperacillin-tazobactam (TZP) in Pseudomonas 
aeruginosa ( PA) pneumonia patients.
Methods: This retrospective study evaluated length of hospitalization, mortality, clinical stability, and time to clinical stability 
with either SI-TZP or PI-TZP therapy in hospitalized patients diagnosed with PA pneumonia between January 01, 2008 and 
June 30, 2014. Patients were included in the study if they received ≥2 days of TZP, were diagnosed with PA pneumonia, and 
had TZP therapy initiated within 3 days of the documented PA infection. 
Results: A similar proportion of patients achieved clinical stability between the PI (n=14, 70%) and SI (n=22, 67%) 
groups, (p=0.8). There was no statistically significant difference in the average time to clinical stability between the PI 
(mean=5.3±3.6) and SI (mean=5.8±6.8) groups, (p=0.77). The total length of stay in the PI group (mean=15.9±9.8) was 
shorter than in the SI group (mean=23.9±33) but did not achieve statistical significance, p=0.2. The 14-day all-cause 
mortality was similar between the two groups, PI (n=1, 5%) and SI (n=2, 6%).
Conclusion: The use of PI TZP was equally effective as standard therapy. Further research is warranted to confirm these 
findings on the clinical benefits of prolonged infusion therapy.
Introduction
Many hospital antimicrobial stew-ardship programs are increas-
ingly using piperacillin-tazobactam as 
a prolonged infusion (PI).1-7 Similar to 
other beta-lactam antibiotics, piperacil-
lin-tazobactam (TZP) is concentration 
independent.8 Its antibacterial effects 
are optimized when the concentration 
of TZP exceeds the minimum inhibi-
tory concentration of the bacterial 
organism for at least 50% of the dos-
ing interval.5 Common prolonged infu-
sion TZP utilizes either 3.375 grams or 
4 grams infused over 4 hours every 8 
hours, whereas standard infusions (SI) 
of TZP are infused over 30 minutes 
every 6 hours. The desired result com-
mon among all hospital stewardship 
programs that implement prolonged 
infusions is improved patient out-
comes while utilizing less TZP.
Several studies evaluated pro-
longed infusion of TZP 2-5, 7, 9 and 
reported a mix of improved mortality 
rates or no difference in treatment out-
come.1-3, 7 The majority of the studies 
were focused on treating gram-nega-
tive infections, with few focusing on 
treating Pseudomonas aeruginosa (PA) 
Research
www.cpha.com   |   Spring 2016   |   California Pharmacist     25
infections. Pseudomonas aeruginosa 
infections are more difficult to treat 
compared to other gram-negative 
pneumonias such as E. coli because 
of the higher minimum inhibitory 
concentrations seen in PA.10 Using 
prolonged infusions to maximize TZP 
exposure in sicker patients with PA 
pneumonia (Acute Physiological and 
Chronic Health Evaluation II scores 
≥17 ) have been shown to reduce 
mortality. Other potential benefits 
found were shorter hospital/intensive 
care length of stay, fewer days on a 
ventilator, and reduced acquisition 
cost compared to standard infusions 
of TZP.1, 11 
Currently, there is limited data on 
the use of prolonged infusion TZP in 
PA infections.3 There is also limited 
information regarding the effects of 
prolonged infusion on achieving clini-
cal stability and time to clinical stabil-
ity in patients with PA pneumonia. The 
aim of this study was to evaluate the 
clinical effect (e.g., clinical stability and 
time to clinical stability) of prolonged 
infusion of TZP compared to stan-
dard infusion in the treatment of PA 
pneumonia. The specific objectives 
of the study were to: 1) Determine 
and compare the length of hospi-
talization and mortality of standard 
and prolonged infusion of TZP in PA 
pneumonia patients, and 2) Determine 
and compare clinical stability and time 
to clinical stability of standard and 
prolonged infusion of TZP in PA pneu-
monia patients.
Prolonged infusion of TZP was 
approved by the Pharmacy and Thera-
peutics Committee and hospital-wide 
conversion was initiated on November 
1, 2011. One of the key components 
to institutional acceptance of pro-
longed infusion was garnering the 
support from the heads of the differ-
ent departments that had high utiliza-
tion of TZP, including internal medicine 
and intensivists. Prolonged infusion 
therapy is not a new concept, and pro-
viding information about which local 
and national institutions have adopted 
this type of therapy and the rationale 
of prolonged infusions diminished 
concerns of deploying nontraditional 
TZP infusions. Another main compo-
nent of programmatic success was 
the hospital-wide use of electronic 
infusion pumps. All the infusion pumps 
were reprogramed with a default TZP 
infusion rate of 13.75 mL/hr, which 
equates to a 4 hour infusion. If a 
patient required a 30-minute infusion 
of TZP, the infusion rate needed to be 
entered manually. Lastly, providing 
education to the nursing and pharmacy 
staff regarding infusion times, dos-
ing adjustments, and compatibilities 
issues was necessary to avoid poten-
tial medication errors.
Prior to November 1, 2011, all 
patients received standard 30-minute 
infusions of TZP, and after the imple-
mentation date, all patients received 
prolonged 4 hour infusions of TZP. The 
multiple strengths (2.25, 3.375, and 
4.5 grams) and dosing frequencies of 
TZP were consolidated into a simpler 
format with prolonged infusion . The 
institution adopted two major formats 
for administering prolonged infusion 
of TZP. It is available as 3.375 grams 
every 8 hours or 3.375 grams every 
12 hours for patients with a creatinine 
clearance of less than 20 ml/min. 
Hemodialysis patients received 3.375 
grams every 12 hours but with a 
30-minute infusion. During the evalu-
ation period prior to implementing the 
prolonged infusion protocol, the avail-
able microbiology records indicated 
that the majority of Pseudomonas 
aeruginosa had a minimum inhibitory 
concentration (MIC) of 8 mg/L. A 4 
hour infusion of 3.375 grams of TZP 
has a >90% probability of attaining the 
target of 50% free drug exceeding the 
MIC.12
Methods
The St. Jude Medical Center 
Institutional Review Board approved 
this retrospective chart-review study. 
This study evaluated all patients with 
PA pneumonia that were hospitalized 
between January 01, 2008 and June 
30, 2014. Patients were selected for 
inclusion in the study if they received 
≥2 days of TZP, were diagnosed with 
PA pneumonia based on International 
Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-
9-CM) code of 482.1 , and had TZP 
therapy initiated within 3 days of the 
documented PA infection. Patients 
were excluded from the study if they 
had isolated a PA resistance to TZP, 
received concomitant effective beta-
lactam therapy for the PA pneumonia, 
were diagnosed with cystic fibrosis, 
or were on hemodialysis. Pharmacy 
utilization records were used in con-
junction with ICD-9 codes to identify 
which patients had PA pneumonia and 
utilization of TZP. If PA pneumonia and 
TZP utilization were isolated on multi-
ple occasions during the study period, 
only the first episode of infection was 
reviewed. Each patient record was 
evaluated to determine inclusion or 
exclusion from the study.
Medical charts for the included 
patients were reviewed for pertinent 
demographic, determination of TZP 
infusion type, laboratory, microbiol-
ogy information, and clinical data to 
determine clinical stability. Patient 
data included age, gender, comorbid 
conditions, intensive care unit (ICU) 
admission, mechanical ventilation, 
length of stay (LOS), onset of infec-
tion location, Pseudomonas aerugi-
nosa MICs, and in-hospital mortality. 
Mortality was defined as all-cause 
mortality of hospitalized patients 
expiring within 14 days after start-
ing the antibiotic regimen. Comorbid 
conditions evaluated included pres-
ence of malignancy, chronic kidney 
disease, diabetes mellitus, and chronic 
obstructive pulmonary disease. A 
Charlson Comorbidity Index (CCI) 
score was calculated at the time TZP 
was initiated to quantify the number 
of comorbid conditions and risk of 
mortality.13 Each comorbid condition 
was identified through medical charts. 
Primary endpoints evaluated were 
clinical stability and time to clinical 
stability. Clinical stability was defined 
as heart rate ≤100 beats/min, systolic 
blood pressure ≥90 mm Hg, respira-
tory rate ≤24/min, oxygen saturation 
≥90%, and temperature ≤37.2°C. 
Time to clinical stability was defined 
as the number of days required for 
clinical stability parameters to return 
to normal values for more than 24 
hours since TZP initiation. Secondary 
endpoints evaluated were all-cause in-
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Characteristics PI (n=20)
 
SI (n=33) P-value
Age (years), median (IQR) 75 (53-79) 69 (64-79) 0.71
Gender
 Male, No. (%) 11 (55) 18 (55) 0.97
 Female, No. (%) 9 (45) 15 (45)
Ethnicity, No. (%)
White 13 (65) 25 (75.8) 0.4
 Others 7 (35) 8 (24.2)
Residence, No. (%)
 Home 16 (80) 22 (66.7) 0.35
 SNF or OSH 4 (20) 11 (33.3)
Comorbidities, No. (%)
 Diabetes Mellitus 5 (25) 5 (15.2) 0.47
 COPD 6 (30) 13 (39.4) 0.49
 Cancer 6 (30) 7 (21.2) 0.47
 Chronic Kidney Disease 3 (15) 2 (6.1) *
 CCI Score, median (IQR) 5 (3.8-7) 5 (4-6) 0.92
 Number of comorbidities, median (IQR) 2 (0.8-4) 1 (1-2) *
Concomitant antibiotics, No. (%)
 Fluoroquinolones 5 (25) 20 (60.6) 0.02
 Aminoglycosides 8 (40) 8 (24.2) 0.23
 Onset of infection, ICU 10 (50) 14 (42.4) 0.59
 Mechanical ventilation, No. (%) 14 (70) 18 (54.5) 0.26
 Days on mechanical ventilation, mean ±SD 16.4±10.3 13.7±13.6 0.51
CrCl (ml/min), No. (%)
 CrCl >50 12 (60) 27 (81.8) 0.08
 CrCl 21-50 5 (25) 4 (12.1) 0.27
 CrCl ≤20 3 (15) 2 (6.1) *
 Duration of therapy (days), mean ±SD 8.4 ±4.3 8.3 ±7.9 0.99
Treatment regimens, No. (%)
         2.25 grams every 6 hours 0 (0) 5 (15.2) *
         3.375 grams every 6 hours 0 (0) 19 (57.6) *
         3.375 grams every 8 hours 16 (80) 9 (27.3) 0.0002
         3.375 grams every 12 hours 3 (15) 0 (0) *
         4.5 grams every 8 hours 1 (5) 0 (0) *
Average TZP gram per patient per day 9.8 11.9
          *Indicates that data cells in one or more cells is too small (<5) to allow the computation of P-value 
 
 TZP: piperacillin-tazobactam, PI: prolonged infusion, SI: standard infusion, SNF: skilled nursing facilities,  
 OSH: outside hospital, COPD: chronic obstructive pulmonary disease, CCI: Charlson Comorbidity Index,  
 IQR: interquartile range, CrCl: creatinine clearance estimated by Cockcroft-Gault
Table 1. Demographic Information of the Patients
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hospital 14-day mortality and LOS. 
Data Analysis
Descriptive statistics were com-
puted for all study variables that 
were measured on an interval or ratio 
scale. Discrete data were presented 
as frequencies and percentages. The 
independent student t-test was used 
to compare mean CCI score differ-
ences, LOS, number of patients who 
achieved clinical stability, and the 
average time to clinical stability by 
the type of infusion received. Either 
Pearson’s chi-square test or Fisher’s 
test was used to measure the associa-
tion between dichotomous variables. 
All tests were two-tailed and a P-value 
of <0.05 was considered significant. 
Statistical analyses were carried out 
with SPSS version 20.0 (Chicago, IL, 
USA) and GraphPad Prism version 6.0 
(San Diego, CA, USA).
Results
During the study period, 122 
patients were identified as having PA 
pneumonia. Fifty-three patients with 
a median age of 72 (SD±15.1) years 
met the inclusion criteria and were 
included in the study. Twenty patients 
received standard infusions of TZP 
and 33 patients received prolonged 
infusions of TZP. The majority of the 
patients were men (55%) and Cau-
casian (72%) who resided at home 
(72%) prior to hospitalization. Baseline 
characteristics are listed in Table 1. 
The demographics of the two 
groups did not differ, with the excep-
tion of concomitant fluoroquinolone 
utilization (PI: 25% vs SI: 61%, 
p=0.02), and type of TZP infusion. 
Table 1 lists different treatment 
regimens used for the Pseudomonas 
pneumonias. The most common regi-
men of the PI group was 3.375 grams 
every 8 hours (n=16, 80%) with 3.375 
grams every 6 hours (n=19, 58%) as 
the most common regimen in the 
standard 30-minute infusion group. 
The average amount of TZP utilized 
was lower in the PI group, (9.8 grams 
vs 11.9 grams). There was no differ-
ence in duration of therapy (mean days 
±SD) between the two groups (PI: 
8.4±4.3 vs SI: 8.3±7.9, p=0.99).
There was no statistically signifi-
cant difference in the proportion of 
patients in the prolonged infusion 
group (n=14, 70%) and the short infu-
sion group (n=22, 67%) who achieved 
clinical stability (p=0.8; Table 2). The PI 
group (n=2, 10%) had a lower number 
of patients who were clinically stable 
at onset of TZP therapy compared 
to the SI group (n=10, 30%). When 
excluding the number of patients that 
were clinically stable at the onset of 
TZP therapy, the PI group (n=12, 60%) 
had higher rates of achieving clinical 
stability compared to the SI group 
(n=12, 36%) but did not reach signifi-
cance, p=0.09. There was no statisti-
cally significant difference in the mean 
time to clinical stability days between 
the PI group (mean = 5.3±3.6) and the 
SI group (mean = 5.8±6.8, p=0.77). 
The total LOS (mean days ±SD) in 
the PI group (15.9 ±9.8) was shorter 
than the SI group (23.9 ±33) but did 
not achieve statistical significance, 
p=0.2. The 14-day all-cause mortality 
was similar between patients in the PI 
group (n=1, 5%) and those in the short 
infusion group (n=2, 6%).
The distribution of MICs can be 
seen in Table 3. The most common 
MIC in each group was 8 mg/L (PI: 
79% vs SI: 48%). The SI group had 
a larger proportion of patients with 
MICs >8 mg/L, (PI: 16% vs SI: 52%, 
p=0.03). Nine patients had susceptibil-
ities performed using the Kirby-Bauer 
Disk Diffusion test and no MICs were 
available.
Discussion
This study evaluated the clinical 
outcomes associated with prolonged 
infusion piperacillin-tazobactam and 
standard infusion therapy for the 
treatment of Pseudomonas aerugi-
nosa pneumonia. Study results show 
that patients who received prolonged 
infusions of TZP achieved similar rates 
of clinical stability to that of standard 
infusion, 70% vs 67%. Additionally, 
the time to clinical stability in the 
prolonged infusion group was similar 
to that of the standard infusion group, 
5.3 days vs 5.8 days. This suggests 
that a 4 hour TZP infusion does not 
delay the time to clinical stability or 
limit the patients’ ability to achieve 
clinical stability. The results of our 
study are similar to others in which 
the use of prolonged infusion of TZP 
was equally effective as standard 
therapy.4, 5, 9 To our knowledge, this is 
the first study that evaluated pro-
longed infusion piperacillin-tazobactam 
for the treatment of Pseudomonas 
aeruginosa pneumonia and associated 
effects on clinical stability and time to 
clinical stability. 
PI (n=20) SI (n=33) P-value
Achieved clinical stability, No. (%) 14 (70) 22 (66.7) 0.80+
Time to clinical stability (days), mean ±SD 5.3 ±3.6 5.8 ±6.8 0.77+
Hospital LOS (days), No. (%)
Post-culture, mean ±SD 11.5 ±6.3 19.8 ±33.0 0.17+
 Total, mean ±SD 15.9 ±9.8 23.9 ±33.0 0.20+
Mortality, 14-day (all-cause), No. (%) 1 (5) 2 (6.1) *
Table 2. Primary Outcomes of the Patients
*Indicates that data cells in one or more cells is too small (<5) to allow the computation of P-value, +independent t-test 
LOS: length of stay
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Similar mortality rates (5% vs 6%) 
and length of stay (16 days vs 24 days) 
were found between the two groups 
in this study, thus further supporting 
that prolonged infusion of TZP is as 
effective as standard infusion therapy 
for the treatment of Pseudomonas 
pneumonia. These results differ from 
those by Lodise et al , who showed 
mortality benefit in patients with ele-
vated Acute Physiology and Chronic 
Health Evaluation and PA infections,3 
probably due to our smaller sample 
size (n=53 vs N=103 PA pneumonias), 
older patient population, and the fact 
that our evaluation was limited to PA 
pneumonia infections.
The main difference between 
the two groups was the amount of 
TZP utilized and the frequency of the 
infusions. On average the prolonged 
infusion group (9.8 grams) used less 
TZP than the standard infusion group 
(11.9 grams). Seventy-three percent 
of the SI group (n=24) received TZP 
doses every 6 hours, but the majority 
of the PI group (n=17, 85%) received 
TZP doses every 8 hours.
Our study has several limitations. 
First, several variables that may 
influence patient outcomes were not 
included on patient charts that were 
utilized for this study. These variables 
include other comorbid conditions or 
co-infections that may prevent clinical 
stability or delay time to clinical stabil-
ity, such as cardiovascular disease. 
Consequently, the Charlson Comor-
bidity Index was used to capture 
the presence of 17 comorbid condi-
tions,13 but the conceded limitation is 
a potential incomplete capture of all 
possible comorbidity information. A 
second limitation is the small sample 
size. The small sample size is a con-
sequence of looking at Pseudomonas 
pneumonia in a community hospital 
with carbapenems as the preferred 
agent, thus limiting the utilization of 
TZP. The antimicrobial stewardship 
program was formalized in the middle 
of 2011 and the majority of patients 
prior to 2011 received a carbapenem 
empirically for the treatment of Pseu-
domonas infections. Lastly, there is a 
discrepancy in the distribution of the 
Pseudomonas aeruginosa minimum 
inhibitory concentrations for TZP. 
In 2012, the Clinical and Laboratory 
Standards Institute (CLSI) lowered the 
susceptibility breakpoint from ≤64/4 
mcg/mL to ≤16/4 mcg/mL. The low-
ered breakpoint introduced a potential 
selection bias with fewer patients in 
the prolonged infusion group having 
MICs higher than 8 mcg/mL. 
As more institutions are consider-
ing the adoption of prolonged infusion 
TZP, the immediate consideration 
is efficacy compared to standard 
therapy. Current clinical evidence 
suggests that prolonged infusion of 
TZP has similar efficacy as standard 
infusions.1-5, 7, 9, 11 Other considerations 
are the financial costs and impact on 
patient care. Using one less dose of 
TZP makes the process financially 
appealing. Standard amounts of 
TZP consumed ranges from 13.5-18 
grams/day . Prolonged infusion of TZP 
would reduce the daily consumption 
to as little as 10.125 grams/day. Pro-
longed infusions may impact patient 
care on multiple levels. Piperacillin-
tazobactam is incompatible with a 
various medications such as amioda-
rone, azithromycin, and pantoprazole.14 
The 4 hour infusion of TZP will limit 
other medications from being infused 
or would require a second intravenous 
access line. Prolonged infusion of 
TZP is also not ideal for patients in 
the emergency department. Having 
patients occupy a bed for 4 hours 
unnecessarily would be counterpro-
ductive in a fast-paced environment. 
Lastly, prolonged infusion of TZP ther-
apy lasts 12 hours a day and will limit 
the activity of ambulatory patients.
Conclusion
As antimicrobial stewardship 
programs implement new ideas into 
practice, it is necessary to review and 
evaluate them to ensure patient safety. 
Currently, there is limited data on the 
benefit of prolonged infusion in Pseu-
domonas infections, with the excep-
tion of reduced antibiotic utilization. 
The study shows that patients receiv-
ing prolonged infusion had similar 
rates of achieving clinical stability and 
took similar amounts of time to clinical 
stability than those receiving standard 
infusion. The use of prolonged infu-
sion of TZP was found to be equally 
effective as standard therapy. Further 
research using a larger sample is war-
ranted to confirm these findings on the 
clinical benefits of prolonged infusion 
therapy.
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